With the gradual maturation of small nucleic acid and antisense nucleic acid drug technologies, as well as the emergence of a series of innovative technologies such as site-specific nucleic acid editing, the development of nucleic acid drugs has entered a new stage of rapid growth.At the same time, the rapid advancement of artificial intelligence (AI) in the medical field is opening up infinite possibilities for target discovery, sequence design, drug delivery, and engineering optimization of nucleic acid drugs.

January 11-12, 2025, the first annual conference hosted by the Southern University of Science and Technology Center of RNA Medicine (SCORE, SUSTech Center of RNA Medicine) will be grandly held in Shenzhen, the core engine city of the Guangdong-Hong Kong-Macao Greater Bay Area. The theme of this conference is "AI-Powered RNA Drug Development"AI-Empowered RNA Medicine" as the theme, focusing on exploring the opportunities and challenges in the field of nucleic acid therapeutics under the AI revolution, showcasing the latest research advancements and application practices.

As a global leader in "AI + Drug Delivery",Dr. Lai Caida, Co-founder & CEO of METiS TechBio, will deliver a speech titled "AI-Driven Drug Delivery and Drug Discovery" on January 11th (Saturday) from 14:25 to 14:50.Keynote Speech。Dr. Lai will share METiS TechBio's leading achievements and practical cases in the field of AI-powered drug delivery and R&D, demonstrating to attendees how to accelerate the development and application of nucleic acid drugs through technological innovation.

This conference willGathering leading researchers in the field of nucleic acid therapy from renowned universities and research institutions both in China and abroad, as well as relevant experts from biotechnology companies, to discuss the opportunities and challenges that the AI revolution will bring to nucleic acid therapeutics, with a focus on AI-assisted nucleic acid drug development. New strategies for nucleic acid drug development in the era of big data and artificial intelligence are also explored.

Learn More About METiS TechBio

METiS TechBio Awarded "National High-Tech Enterprise" Recognition